INTRODUCTION AND OBJECTIVES: Office evaluation and management (E&M) visits are the most common physician services and accounted for approximately $23 billion in Medicare spending in 2017. Currently, these visits are reimbursed according to visit complexity at 5 levels. Recently, the Centers for Medicare & Medicaid Services has proposed setting one payment level for all level 2 through 5 visits. This change, they propose, will help simplify billing and documentation, reduce the potential for fraud, and have only a minor impact on physician reimbursement. However, the impact on different types of physician practices is not known. Therefore, we aimed to assess the effect of this policy change on Medicare reimbursement for urology practices.
INTRODUCTION AND OBJECTIVES: Office evaluation and management (E&M) visits are the most common physician services and accounted for approximately $23 billion in Medicare spending in 2017. Currently, these visits are reimbursed according to visit complexity at 5 levels. Recently, the Centers for Medicare & Medicaid Services has proposed setting one payment level for all level 2 through 5 visits. This change, they propose, will help simplify billing and documentation, reduce the potential for fraud, and have only a minor impact on physician reimbursement. However, the impact on different types of physician practices is not known. Therefore, we aimed to assess the effect of this policy change on Medicare reimbursement for urology practices.
METHODS: Using a 20% sample of national Medicare claims data linked with the Medicare Data on Provider Practice and Specialty file, we identified all group practices with at least one urologist in 2015.
For each group, we characterized group practice type (solo, single specialty, or multispecialty) and academic affiliation. For each practice, we examined all office E&M visits and calculated current payments as well as hypothetical payments under the proposed policy. We then determined the change in each practice's Medicare revenues and used multiple linear regression to identify predictors of decreased revenues.
RESULTS: We identified 2,822 practices: 1,033 (36.6%) were multispecialty groups, 1,372 (48.6%) were solo groups, and 417 (14.8%) were single specialty urology groups. As a result of the E&M payment change, half of urology practices would earn at least 1.3% higher Medicare revenues. However, there was considerable variation, with the potential impact ranging from -42% to 56% of total Medicare professional fees. In total, 37.6% of practices would have reduced Medicare revenues and 11.7% of practices would lose more than 5% of their Medicare payments for the year. Academic medical groups were primarily multispecialty groups and accounted for 116 (4.1%) practices. The majority of academic medical groups (63.8%) would have reduced revenues ( Figure) .
CONCLUSIONS: On average, urology practices stand to benefit from the proposed change to E&M reimbursement. However, groups with a high proportion of level 4 and 5 office visits, particularly academic medical groups, will have significantly diminished Medicare revenues.
Source of Funding: This work was supported by NIA R01AG048071 (BKH) and NCI F32CA232332 (PKM)
PD67-02 CORRELATION OF RELATIVE VALUE UNITS WITH SURGICAL COMPLEXITY AND PHYSICIAN WORKLOAD IN UROLOGY
Zoe Gan, Case Wood*, Allison Deal, Chang Xu, Yue Wang, Angela Smith, Raj Pruthi, Chapel Hill, NC INTRODUCTION AND OBJECTIVES: Work relative value units (RVUs) represent a metric of physician productivity, but the correlation between RVUs and surgical complexity remains poorly understood. Our primary objective was to define the correlation of RVUs with measures of surgical complexity and physician workload in the field of urology. We hypothesized that RVUs would correlate poorly with these measures. Our secondary objectives were to 1) identify procedures with outlying RVU values for their measures of surgical complexity and workload and 2) calculate projected RVU values for these procedures.
METHODS: We retrospectively reviewed the 2012-2016 American College of Surgeons National Surgical Quality Improvement Program (NSQIP) databases, from which we selected 56 current procedural terminology (CPT) codes representing the spectrum of urologic surgery. Linear regression was used to correlate RVUs with length of hospital stay (LOS), operating room (OR) time, morbidity, mortality, serious adverse events (SAEs), and readmissions. Variables with R2>0.7 were incorporated into a multivariable model. Studentized residuals were used to identify outlying procedures. For outlying procedures, projected RVU values were estimated based on the regression model. Outlying procedures identified using the multivariable regression model were retroperitoneal lymph node dissection (projected þ10.64 RVUs), laparoscopic partial nephrectomy (projected -6.83 RVUs), laparoscopic ureteroneocystotomy (projected -6.78 RVUs), and cystectomy with bilateral pelvic lymphadenectomy (projected þ6.54 RVUs).
CONCLUSIONS: In urology, certain measures of surgical complexity and physician workload appear to correlate with RVUs more than others. Incorporating objective data may improve RVU assignments for individual CPT codes in the future.
INTRODUCTION AND OBJECTIVES:
Surgical care makes an outsized contribution to Medicare payments, accounting for more than half of program spending (w$120 billion per year). Many hope that the collective incentives of Medicare accountable care organizations (ACOs) will help lower expenditures on surgery. However, the impact that ACO policy has had on surgical care remains unclear.
METHODS: We analyzed a 20% sample of national Medicare data (2012 to 2015), identifying fee-for-service beneficiaries who were aligned and unaligned with a Shared Savings Program ACO. For each beneficiary, we then calculated total price-standardized annual payments made on his behalf for urologic procedures (based on Current Procedural Terminology codes 50000 to 55999). Using an interrupted time series research design, we then fit multivariable linear models, adjusting for age, gender, race, level of comorbid illness, socioeconomic status, and hospital referral region, to estimate the association between per beneficiary annual spending on urologic procedures and ACO status. Finally, we used multivariable negative binomial regression to determine whether the number of surgical episodes that a patient undergoes relates to his ACO status.
RESULTS: We identified 19,065,107 beneficiary-year observations, 15.4% of which were aligned with an ACO. ACO alignment was associated with a savings on urologic surgery of $22 [95% confidence interval (CI), 15 to 29; P<0.001) per beneficiary-year (Table) . This difference was driven by reduced spending on inpatient procedures (-$20; 95% CI, -$26 to -$13; P<0.001). While ACO alignment was not associated with a difference in the number of surgical episodes per beneficiary (relative rate, 0.99; 95% CI, 0.97 to 1.01; P[0.47), ACO-aligned beneficiaries underwent 5.8% fewer inpatient procedures than unaligned ones (0.94; 95% CI, 0.92 to 0.97; P<0.001).
CONCLUSIONS: Medicare ACOs reduced spending per beneficiary per year on urologic care by $22. To provide perspective, if unaligned beneficiaries had a similar reduction, Medicare would have realized $416 million in savings over the study period. Spending reductions were driven, in part, by fewer inpatient surgical episodes. METHODS: Using the 20% Medicare sample, men with incident prostate cancer were identified. The ACO cohort consisted of men with providers in the Medicare Shared Savings Program -which is currently the largest ACO program in the United States. Prostate cancer expenditures were calculated by subtracting total charges from the year prior to diagnosis. Propensity score weighting was used to balance baseline characteristics of men treated in ACOs and non-ACOs, and between treatment modalities (radiation, prostatectomy and observation/surveillance). A propensity score weighted regression model was then used to estimate mean expenditures for men treated in ACOs and non-ACOs and to test the association between ACO status and prostate cancer expenditures.
RESULTS: In total, 3,297 men were treated in ACOs for localized prostate cancer, versus 24,088 in the non-ACO cohort. The weighted total charges for each treatment modality were $32,358 (radiation) $27,662 (prostatectomy) and $11,134 (observation/ surveillance). In our propensity score weighted regression model, the association between charges and ACO status was not significant, nor was the interaction between treatment type and costs. This was true both overall, and in a stratified analysis by treatment type.
CONCLUSIONS: There was no significant difference in Medicare spending on prostate cancer care based on provider ACO affiliation, regardless of treatment type. While the effects of ACOs on clinical care are complex, this study adds to a growing body of evidence suggesting that ACOs may fail to achieve significantly reduce costs in certain clinical settings such as prostate cancer.
